Previous 10 | Next 10 |
Gainers: Camber Energy (NYSEMKT: CEI ) +61% . More news on: Camber Energy, Inc., Cancer Genetics, Inc., Micron Solutions, Inc., Stocks on the move, , Read more ...
SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initiated the next phase of its collaboration with Celularity, Inc., a Warren, New Jersey, based clinical-stage cell therapeutics company delivering transformative allogenei...
SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic pro...
Deals and Financings Abbisko Therapeutics, a Shanghai novel drug biopharma, raised $70 million in a Series C financing led by Singapore's Temasek. The company has four clinical programs underway, and it intends to expand its discovery pipeline, which consists of small molecule targeted oncol...
These Penny Stocks Are Reporting Key Data This Week Looking for penny stocks to buy can be a task especially if there are many to choose from. When it comes to weekend research one of the main search topics involves potential catalysts. So you might say, “It’s the weekend, no o...
STI-6991 is an I-Cell TM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virus The I-Cell vaccine is expected to elicit both T cell and B cell immunities against SARS-CoV-2 Sorrento is in ac...
Sorrento Therapeutics ( SRNE +1.2% ) inks an agreement with China-based Mabpharm Limited for exclusive North American and European rights to one of its fusion proteins for the potential treatment of COVID-19. More news on: Sorrento Therapeutics, Inc., Healthcare stocks news, Stocks on ...
ACE-MAB TM is a proprietary bi-specific fusion protein that binds to the spike protein of coronaviruses, including SARS-CoV-2 and SARS-CoV, which is expected to block SARS-CoV-2 from binding and infecting respiratory epithelial cells or ACE2-expressing cells to interrupt the viral life cy...
SAN DIEGO and BOSTON, March 23, 2020 (GLOBE NEWSWIRE) -- In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) and SmartPharm Therapeutics Inc. (SmartPharm) today announced a research and development collaboration to ...
March 23, 2020 Palm Beach, FL – March 23, 2020 – In the months since the global public health crisis rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic. The crisis has catalyzed ...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Fuse Medical Inc (FZMD) is expected to report for Q1 2024 PhoneX Holdings Inc (PXHI) is expected to report for Q1 2024 Avalon GloboCare Corp. (ALBT) is expected to report for Q1 2024 Ricoh Company Ltd ADR (RICOY) is expected to report for Q4 2024 Amplitech Group Inc. (AMPG) is exp...
Inpixon (INPXV) is expected to report for Q1 2024 Siebert Financial Corp. (SIEB) is expected to report for Q1 2024 Greenwave Technology Solutions Inc. (GWAV) is expected to report for Q1 2024 Bank Hapoalim B.M. ADR (BKHYY) is expected to report for Q1 2024 Gelesis Holdings, Inc. (...
Sorrento Therapeutics Inc. (SRNE) is expected to report for Q1 2023